# Prevention of Methamphetamine Use among Postpartum Women (PROMPT)

> **NIH NIH R21** · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · 2022 · $76,750

## Abstract

PROJECT SUMMARY
PRevention Of Methamphetamine Use among Postpartum Women Trial (PROMPT) is a randomized controlled
trial of postpartum individuals with methamphetamine use disorder to micronized progesterone or placebo. This
research study is pursuing two specific aims: (1) To assess feasibility, safety, and preliminary efficacy of
micronized progesterone to decrease return to methamphetamine use among postpartum individuals with
methamphetamine use disorder; (2) To evaluate the association between salivary allopregnanolone levels and
methamphetamine craving in control and treatment groups. For Aim 1, we are randomizing 40 postpartum
individuals with methamphetamine use disorder within 12 weeks of the end of pregnancy who have achieved
abstinence for four weeks to micronized progesterone or placebo and will assess methamphetamine use over
12 weeks. We are tracking enrollment and retention of postpartum individuals, safety of this intervention and
establishing preliminary efficacy of progesterone to reduce return to methamphetamine use. For Aim 2, we are
testing the hypothesis that increased allopregnanolone levels, an active metabolite of micronized progesterone,
are correlated with reduced methamphetamine cravings among postpartum individuals. Our long-term goal is
to advance the understanding of how postpartum individual’s unique physiology impacts methamphetamine use
disorder and to apply this knowledge to developing novel interventions aimed at reducing methamphetamine use
in this population. This project is innovative as it addresses a significant health issue facing this vulnerable
population with a novel intervention. The proposed research is significant because of its potential to improve
public health by decreasing methamphetamine use among postpartum women and to advance scientific
knowledge by investigating the association between allopregnanolone and methamphetamine cravings. The
rationale for this supplement to the parent grant is to address the Principal Investigator’s qualifying life event
which delayed the start-up of PROMPT study. The supplement’s funding will be used to fund research
coordinator time to continue recruitment, enrollment and retention of participants in the PROMPT study.

## Key facts

- **NIH application ID:** 10631709
- **Project number:** 3R21DA053463-02S1
- **Recipient organization:** UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH
- **Principal Investigator:** Marcela Smid
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $76,750
- **Award type:** 3
- **Project period:** 2022-06-01 → 2024-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10631709

## Citation

> US National Institutes of Health, RePORTER application 10631709, Prevention of Methamphetamine Use among Postpartum Women (PROMPT) (3R21DA053463-02S1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10631709. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*